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Despite decades of research, HIV remains a global health threat. Issues of multi-drug resistance and lack of an effective vaccine have recently
led to the targeting of host factors for anti-viral drug development. While a few genome-wide screens for novel HIV co-factors have been reported,
the promise of finding a therapeutic target has yet to be realized. Here, we report a screen of a cDNA library representing 15,000 unique genes in
an infectious HIV system, and show that genomic screening can lead to the identification of novel proviral host factors. Mixed lineage kinase 3
(MLK3/MAP3K11) was identified as one of the strongest enhancers of infection and mutant studies show that its activity is dependent on its
kinase function. Consistent with its known role in the activation of the AP-1 pathway through JNK kinase, MLK3 was able to enhance Tat-
dependent HIV transcription in vitro thus leading to an increase in infection signal. RNA interference studies confirm the involvement of
endogenous MLK3 in HIV infection, further implicating this kinase as a potential therapeutic target.
© 2007 Elsevier Inc. All rights reserved.Keywords: Cellular co-factors in HIV replication; Genomic screeningIntroduction
The advent of highly active anti-retroviral therapy (HAART),
which combines several drugs against one or more viral targets,
to treat HIV patients led to radically reduced viral load and
maintained immune function in patients with access to therapy.
However, the low fidelity of genomic replication mediated by
reverse transcriptase generates mutations in the viral genes that
render them resistant to anti-viral drugs (Parienti et al., 2004).
Because of the small size of the viral genome, HIV relies heavily
on the host cell machinery to complete its life cycle. The first
efforts at targeting host factors for anti-viral therapy have
focused on the receptor (CD4) and co-receptor (CCR5 and
CXCR4) (Seibert and Sakmar, 2004) but compounds that block
these proteins have not yet reached the clinic. Although we
know about several other critical host factors involved in HIV
infection, such as the proviral TSG101 (Demirov et al., 2002)⁎ Corresponding author.
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doi:10.1016/j.virol.2006.11.036and anti-viral APOBEC3G (Harris and Liddament, 2004), there
are likely many more that remain undiscovered.
On the heels of drug discovery, high-throughput genomic
screening has emerged as the newest tool for rapidly identifying
the individual players in a pathway of interest. The most widely
used method for genome screening, the yeast-two-hybrid screen,
quickly yields a pool of potential interacting partners. However,
proving that the interaction is present and physiologically
relevant in mammalian cells is more challenging. The nature of
the yeast-two-hybrid system can also lead tomany false negatives
and false positives due to the hybrid protein structures and
potentially altered behavior in the yeast cell nucleus (Colland and
Daviet, 2004). Newer methods have employed screening of
genomic libraries in mammalian cells, including both loss-of-
function and gain-of-function screens. Pooled expression
libraries have been used to isolate important immune receptors
such as CD2 (Seed and Aruffo, 1987). Pathway dissection
through disruption of gene expression has been achieved using
siRNA/shRNA (Nguyen et al., 2006; Vanhecke and Janitz, 2004;
Willingham et al., 2004), as well as by expression of genetic
suppressor elements (GSEs) (Gudkov et al., 1993) and ribozymes
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mammalian cell lines that are easily transfected with high
efficiency, movement of genomic libraries to viral vector systems
(Lorens et al., 2001) and the development of high-throughput
electroporation (Yamauchi et al., 2004) will soon expand the
potential for discovery to any pathway in any desired cell type.
Functional genomic screening offers the opportunity to
rapidly find novel host factors involved in HIV biology that
could be exploited as potential therapeutic targets. We therefore
performed a high-throughput screen of a cDNA library of
15,000 unique genes to find novel proviral factors whose
overexpression would lead to enhancement of HIV-IIIb
infection (library details at http://function.gnf.org). From the
pool of top enhancers chosen for follow-up, 13 host factors with
no known connection to HIV infection continued to confirm
with levels of enhancement from 2- to 8-fold over control.
RNAi-mediated depletion of endogenous levels of several
cDNA hits, including IFIT1, DNAJC14, and PITPN, inhibited
HIV infection. Because of its clear role in pathways known to be
utilized by HIV and potential for small molecule intervention,
we chose to focus on the cDNA hit mixed lineage kinase 3
(MLK3/MAP3K11) for further follow-up. Studies with a
kinase-inactive mutant form of MLK3 showed that kinase
activity was necessary for HIVenhancement. Consistent with its
role in AP-1 activation, MLK3 overexpression was shown to
increase Tat-dependent transcription, providing a mechanism
for its viral effects. RNA interference studies showed an
inhibition of HIV infection following MLK3 depletion,
confirming a role for endogenous MLK3 in the HIV life cycle.
Results
Because of their ease of transfection, we employed HIV
permissive HeLaCD4βgal cells for screening of a 15,000 geneFig. 1. High-throughput cDNA screen layout, performance of controls and families o
(Tat-Sport6) cDNAs were spotted into the wells of a 384-well opaque plate containin
and Tat-responsive reporter plasmid LTR-Luc. After complex formation, HeLaCD4β
was added. Three days later, levels of infection were assessed by measuring luciferas
chosen for follow-up. Genes were chosen based on their screen performance and lithuman cDNA library using a reverse transfection protocol
previously described (Chanda et al., 2003). Negative control
(Sport6-gfp) and positive control (Tat-Sport6) cDNAs were
spotted into wells of 384-well plates containing the library
cDNA (one gene per well) followed by the addition of
transfection reagent solution containing an LTR-luciferase
reporter construct responsive to HIV Tat (Fig. 1A). Cells were
added after complex formation, and after 24 h, each well was
infected with HIV-IIIb. Infection was allowed to proceed for
3 days to allow for effects on all stages of infection from entry to
release and spread throughout the culture to be observed. The
use of this multi-day infection assay to investigate effects
throughout the viral life cycle was demonstrated previously by
the ability of siRNA against CXCR4 (early stage), Furin
(middle stage) and TSG101 (late stage) to effectively decrease
the infection signal (Nguyen et al., 2006). Infection in the
cDNA screen was assessed by measuring the amount of
luciferase produced via the viral LTR promoter using an
equivalent input of Tat cDNA (40 ng) as the positive control.
The entire screen was performed in duplicate in order to assess
variability. The data for each cDNA were compared to the
median signal of the entire plate and expressed as the ratio afa/
mfa, which is the average fold activation (afa) divided by the
adjusted standard deviation of the fold activation (mfa). The
mfa in effect penalizes the value for fold activation if the
standard deviation between the replicates is high, allowing hits
to be identified as those that enhanced infection reproducibly
(see Materials and methods for analysis of details). Over-
expression of the positive control Tat showed a distribution of
response with a mean approximately two standard deviations
from that of the negative control, empty Sport6-gfp (data not
shown). Hits were defined as those cDNAs whose enhancement
of infection was at least 2-fold over the plate median, a level
which was close to the mean of the Tat-positive control.f hits. (A) Negative control (Sport6GFP) and positive control for enhancement
g one cDNA/well of the library followed by the addition of transfection reagent
gal cells were added and incubated overnight, after which HIV-IIIb (4 ng/well)
e produced from the reporter using Brite Glo. (B) Families of the enhancing hits
erature review.
Table 1
Gene ontology analysis of cDNA screen hits
Database ID a Description # of hits Hits LogP
GO:0046785 Microtubule polymerization 2 MAPT, CENPJ −3.327
IPR012956 CBF, N-terminal 2 HNRPAB, HNRPD −3.297
GO:0003746 Translation elongation factor activity 4 EEF1A2, EEF1G, TUFM, SUPT16H −3.224
IPR002475 BCL2-like apoptosis inhibitor 3 BCL2A1, BCL2L1, BCL2L13 −2.921
IPR002048 Calcium-binding EF-hand 11 AIF1, POLR2C, PPEF1, S100A12, S100P, SLC25A12,
RASGRP1, KCNIP1, USP32, REPS1, MRLC2
−2.905
GO:0003729 mRNA binding 4 HNRPAB, HNRPD, HNRPDL, TNRC4 −2.877
GO:0050773 Regulation of dendrite morphogenesis 2 DBN1, MT3 −2.856
IPR011992 EF-hand type 11 AIF1, PPEF1, S100A10, S100A12, S100P, SLC25A12,
RASGRP1, KCNIP1, USP32, REPS1, MRLC2
−2.72
GO:0050767 Regulation of neurogenesis 3 DBN1, MAPT, MT3 −2.715
GO:0019867 Outer membrane 5 BCL2L1, TIMM23, NUP62, NUP133, TOMM22 −2.647
IPR003093 Apoptosis regulator Bcl-2 protein, BH4 2 BCL2L1, BCL2L13 −2.532
IPR000712 Apoptosis regulator Bcl-2, BH 3 BCL2A1, BCL2L1, BCL2L13 −2.468
IPR001751 Calcium-binding protein, S-100/ICaBP type 3 S100A10, S100A12, S100P −2.468
GO:0042221 Response to chemical stimulus 12 CCR1, HSPA1L, HSP90AB1, PLP2, RNASE2, S100A12,
CCL5, SPP1, ABCG2, NUP62, KCNIP1, DERL1
−2.428
GO:0009628 Response to abiotic stimulus 13 CCR1, FECH, HSPA1L, HSP90AB1, PLP2, RNASE2,
S100A12, CCL5, SPP1, ABCG2, NUP62, KCNIP1, DERL1
−2.367
GO:0016358 Dendrite morphogenesis 2 DBN1, MT3 −2.346
GO:0008159 Positive transcription elongation factor activity 2 HMGN1, SUPT16H −2.317
a Identification number of represented family in either the GO or Interpro (IPR) databases.
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infection with an afa/mfa ≥2, the cutoff chosen for follow-up.
Several genes already known to be involved in HIV infection,
such as the enhancers S100A12 (Ryckman et al., 2002), PP2A
regulatory subunit B (Hrimech et al., 2000), nuclear exportin
CRM1 (Wodrich and Krausslich, 2001) and CDK2 (Ammosova
et al., 2005), were identified as enhancers by the screen, serving
as an internal validation. The list of screen hits was then
analyzed for identification of statistically over-represented
(logP≤−2.3) functional categories by comparing to the GO
and Interpro databases of gene families (Table 1). Several
families representing genes involved in enhancing cellular
metabolism (mitochondrial genes), gene transcription andTable 2
Top cDNA enhancers of HIV infection in HeLaCD4βgal cells
Gene hit Accession # Symbol Funct
Phosphatidylinositol transfer protein alpha NM_006224 PITPNα Cytos
Extracellular link domain containing 1 NM_006691 XLKD1 Recep
Tripartite motif-containing 28 NM_005762 TRIM28 Trans
Lysozyme NM_000239 LYZ Bacte
Interferon-induced protein with
tetratricopeptide repeats 1
NM_001548 IFIT1 IFN a
Coronin, actin binding protein, 1A NM_007074 CORO1A Phago
Clone PP902 AF218032 Unkn
DnaJC14 protein NM_032364 Chap
Aldehyde dehydrogenase 3 family, memberA1 NM_000691 ALDH3A1 Oxidi
SET domain-containing protein 8 AY102937 SET8 Histo
Mitogen-activated protein kinase kinase
kinase 11
NM_002419 MAP3K11,
MLK3
Regu
KIAA0247 gene product NM_014734 Mem
Dual specificity phosphatase 18 XM_038481 DUSP18 Ser/T
a Average fold activation (afa) divided by the adjusted standard deviation of the f
deviation between the replicates.
b Negative control Sport6gfp, same as used in screen.translation enhanced HIV infection, as well as many proteins
that inhibit cellular apoptosis. Because HIV relies heavily upon
the host cell machinery in order to carry out its life cycle, those
proteins involved in increasing basic cellular metabolic and
replicative functions while preventing cell death would be
expected to be identified as hits in this cDNA screen. HIV
utilizes the microtubule network for particle entry and
translocation into the nucleus, and chemicals that destabilize
microtubules block infection (Matarrese and Malorni, 2005;
McDonald et al., 2002). Interestingly, several families with
proteins known to be involved in microtubule dynamics
(MAPT, DBN1) were identified in the screen, which may also
suggest additional roles for them in HIV infection. The familiesion Original hit
afa/mfa a
Reconfirmation
fold over control b
olic lipid transport and vesicle trafficking 2.77 2.95
tor for hyaluronan 2.60 2.7
criptional corepressor 2.67 5.8
rial cell wall degradation 2.67 8.6
lpha induced expression, unknown function 4.90 3.5
some formation, and motility 2.90 2.92
own function 2.47 2.4
erone 5.70 5.5
zes aromatic aldehyde substrates 2.07 1.70
ne H4-lysine 20-specific methyltransferase 2.13 2.2
lator of JNK kinase, IKK alpha and beta 4.60 8.80
brane protein, unknown function 3.90 2.01
hr and Tyr phosphatase, unknown function 2.99 2.10
old activation (mfa), which accounts for both the effect of each cDNA and the
Fig. 2. Efficacy of siRNA targeting top non-druggable cDNA hits in
HeLaCD4βgal cells. SMARTPool siRNAs against the top cDNA hits were
transfected into HeLaCD4βgal cells and after 24 h, cells were challenged with
HIV-IIIb (A). Infection was assessed after 3 additional days by measuring the
beta-galactosidase produced from the stable LTR-βgal reporter within the cells
using a chemiluminescent substrate (Gal Screen). Cytotoxicity of each siRNA
was also determined by using Cell Titer Glo in parallel uninfected cultures. Of
those SMARTPools tested, three showed inhibition of infection without
significant toxicity compared to control and are shown here (PITPN, IFIT1,
DNAJC14). (B) To ensure proper target knockdown, SMARTPools were
transfected in parallel wells and RNA harvested at 24 h post-transfection. Levels
of each gene were then determined using TaqMan quantitative RT-PCR and
normalized to an internal rRNA component reference standard 36B4. Percentage
of gene knockdown was calculated relative to the GL2-negative control and is
representative of at least two experiments.
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enhancer S100A12, were also statistically significantly repre-
sented in the hitlist, which may lead to a broader understanding
of the involvement of this class of proteins as a whole in
infection. In addition, several novel protein families, including
those with protein methyltransferase activity (GO:0008276) and
from the peptidase M24 family (IPR000994), were identified
that could lend further insight into HIV biology.
The top enhancers of infection, as determined both by screen
performance and literature review, were chosen for follow-up.
The hits represented a variety of gene families including
enzymes and transcription factors and genes from pathways
known to be important in HIV infection, such as the ubiquitin
pathway (Fig. 1C). Each cDNA hit was re-grown at mini-prep
scale and re-tested in the original assay, and then the top
performers were grown at maxi-prep scale, tested in the original
assay, and sequenced to ensure proper hit identity. At this stage,
13 sequence-confirmed hits continued to show enhancement of
activity compared to the negative control, ranging from 1.7-fold
to 8.8-fold over Sport6-GFP-negative control (Table 2).
Because the exact biological function of several of these factors
is either unknown or inferred, investigation into their role in
HIV biology will also allow insight into their cellular functions.
We next investigated whether the seven strongest cDNA
enhancers (performing ∼3-fold or greater over control) were
essential for HIV replication by depleting the endogenous
proteins in HeLaCD4βgal cells using siRNA. For 6 of these we
obtained validated siRNA SmartPools and evaluated their
effects on HIV-IIIb infection in HeLaCD4βgal cells. Of those
tested, siRNA against chaperone DnaJC14, interferon-induced
protein with tetratricopeptide repeats 1 (IFIT1) and phosphati-
dylinositol transfer protein alpha (PITPNá) decreased HIV
replication without significant toxicity (Fig. 2A) further
strengthening their role in infection while the others had no
effect on viral replication or cell viability (data not shown).
Quantitative RT-PCR was used to ascertain the ability of these
siRNAs to knock down the target gene of interest in this system
(Fig. 2B). There are several reasons why host factors that were
identified by cDNA screening may not be confirmed in siRNA
studies. Because cDNA screening involves the introduction of
genes normally expressed in a variety of tissues, the effects seen
may not be supported by RNA interference due to lack of
adequate expression or function of those genes in the cellular
assay system. Identification of putative host factors through
cDNA screening then serves as a starting point to focus further
efforts in cellular co-factor studies. In addition, overexpression
of any protein may lead to effects outside the normal scope of
physiologic function. Thus, proteins such as lysozyme, whose
normal activity is the breakdown of bacterial cell wall
components as part of the innate immune system, may exhibit
alternative activities such as enhancement of HIV infection
when overexpressed, even if this function may not be
physiologically relevant or mechanistically obvious.
In light of its clear physiologic role and high potential as a
therapeutic target, we next focused our efforts on the strong
cDNA enhancer mixed lineage kinase 3 (MLK3). This serine/
threonine kinase is involved in the activation of downstreamMap kinases, including JNK, p38, and ERK and has been
shown to play a critical role in neuronal apoptosis including that
mediated by HIV gp120 (Bodner et al., 2004; Gallo and
Johnson, 2002). A compound inhibitor of MLK3, CEP-1347,
was in clinical trial for the treatment of neurodegenerative
diseases, highlighting its role in neuronal cell death and its
applicability as a drug target (Bodner et al., 2004). To address
whether the kinase activity of MLK3 was responsible for the
enhancement of infection seen using the cDNA, we obtained a
kinase-inactive mutant (MLK3 KI) and tested its effects on HIV
infection. Unlike the wild-type protein, MLK3 KI was unable to
increase infection, suggesting that the function of MLK3 is
critical for enhancement (Fig. 3A). Because of its role in
activating the AP-1 complex through JNK activation, we
hypothesized that MLK3 could be acting by enhancing HIV
transcription via the AP-1 site located in the HIV LTR (Cullen,
1991b). In support of this hypothesis, overexpression of wild-
type MLK3, but not the kinase-inactive mutant, led to increases
in overall JNK phosphorylation (data not shown). To test
whether this could be responsible for enhanced HIV transcrip-
tion, MLK3 was co-transfected with the LTR-luciferase
construct either with a Tat expression vector or a control
plasmid to assess both Tat-dependent and Tat-independent
Fig. 3. (A) Effect of kinase-inactive MLK3 (K144R) on HIV infection of
HeLaCD4βgal cells. Cells were co-transfected with cDNA encoding wild-type
MLK3, kinase-inactive MLK3 (K144R), or control plasmid along with a
luciferase reporter under the control of the HIV-LTR followed after 24 h by
infection with HIV-IIIb. Infection was assessed after 3 days by measuring
luciferase activity using Brite Glo. The kinase-inactive mutant was unable to
increase infection, highlighting the requirement of kinase function for the
enhancement seen by wild-type MLK3. Data are shown as the fold enhancement
over negative control plasmid and are the summary of four independent assays
with two replicates in each assay. (B) Effect of MLK3 overexpression on HIV
transcription. HeLaCD4βgal cells were co-transfected with cDNA encoding
wild-type MLK3 or control plasmid (pcDNA3) along with a luciferase reporter
under the control of the HIV-LTR (LTRLuc) and either a Tat expression vector
(Tat) or control vector Sport6-GFP (S6G) to assess either Tat-dependent or Tat-
independent transcription. Transcription was assessed after 2 days by measuring
luciferase activity using Brite Glo. Expression of MLK3 enhanced Tat-
dependent transcription of luciferase, but had minimal effect on Tat-independent
transcription. Data are shown as the average fold enhancement with MLK3 (e.g.,
MLK3/Tat/LTRLuc) over negative control plasmid (e.g., pcDNA3/Tat/
LTRLuc), and are the summary of two independent assays with two replicates
in each assay.
Fig. 4. Efficacy of siRNA targeting MLK3 against HIV infection. Individual
MLK3 siRNAs were transfected into HeLaCD4βgal cells (A and B) or
electroporated into Jurkat cells (C and D) and after 24 h, cells were challenged
with HIV-IIIb. For HeLaCD4βgal cells (A), infection was assessed after 3
additional days by measuring the beta-galactosidase produced from the stable
LTR-βgal reporter within the cells using a chemiluminescent substrate (Gal
Screen). For Jurkat cells (C), input virus was removed 24 h after infection, and
supernatants were collected after an additional 48 h and tested for levels of p24
by ELISA. Cytotoxicity of each siRNAwas also determined by using Cell Titer
Glo in parallel uninfected cultures. Data are shown as the percent infection
inhibition or cytotoxicity compared to control GL2 siRNA deviation and are the
average±standard deviation of at least three independent experiments with
twelve replicate wells per experiment. To evaluate depletion of target proteins,
HeLaCD4βgal cells (B) or Jurkat cells (D) were harvested after 72 h and for
MLK3. All three siRNAs were able to significantly deplete endogenous MLK3
levels. The extent of protein depletion in the Jurkat cells is less than in the
HeLaCD4βgal cells, explaining the lower level of infection inhibition seen.
20 D.G. Nguyen et al. / Virology 362 (2007) 16–25effects on LTR-mediated transcription. Expression of MLK3
enhanced Tat-dependent transcription by approximately 3-fold
over control but had no significant effect on Tat-independent
transcription (Fig. 3B), suggesting that MLK3 enhances
infection through viral-specific transcription. The level of Tat
plasmid used in the co-transfection studies (40 ng) was the same
level used as a positive control for the screen and showed
maximal possible activation within this cellular system in a dose
response study (data not shown). This indicates that over-
expression of MLK3 can enhance viral-specific transcription
above and beyond that seen with Tat alone in this system.
Considering the overexpression data, we finally investigated
whether siRNA against MLK3 would inhibit HIV infection.
We obtained three unique siRNA sequences targeting MLK3
and evaluated their efficacy against HIV in HeLa-CD4-βgal
cells. All three siRNAs were effective at depleting MLK3
protein (Fig. 4B) and decreased HIV infection by approxi-
mately 40% (Fig. 4A). Consistent with its proposed mechanism
of affecting Tat-dependent transcription, MLK3 depletion hadno effect on levels of early reverse transcripts or integrated
provirus (data not shown). We further tested MLK3 siRNA in
HIV-IIIb infection of Jurkat cells, and found that it decreased
infection, although to a lesser extent than that seen in the
HeLa-CD4-Bgal cells (Fig. 4C). Western blot analysis showed
that the amount of protein depletion in the Jurkat cells was
lower than that seen in the HeLaCD4Bgal cells, thus explaining
the lower level of inhibition seen (Fig. 4D). Along with recent
evidence showing a lack of gross defects in MLK3 knockout
mice (Brancho et al., 2005), these results indicate that MLK3 is
21D.G. Nguyen et al. / Virology 362 (2007) 16–25a novel proviral host factor that could serve as a therapeutic
target for HIV infection.
Discussion
The increasing incidence of transmission of multi-drug
resistant virus and lack of an effective vaccine has led to a
search for novel targets for anti-HIV therapy. The hope is that
candidates can be identified that are necessary for viral
replication but dispensable for overall cellular function, leading
to a therapeutic window that allows infection inhibition without
significant host toxicity. There are many reports in the literature
using yeast-two-hybrid screening and microarray analysis to
identify new cellular co-factors, however, little genome-scale
screening within the context of a productive infection with live
HIV has been reported. Because it involves the introduction of
genes, cDNA screens like the one presented here allow for the
identification of cellular co-factors that would be utilized in the
physiologic cellular targets for HIV in cell types more amenable
to screening, such as HeLaCD4βgal cells. In reviewing the data
from the screen and choosing hits for follow-up, we focused on
genes whose expression profiles showed at or above median
expression in T cells or monocytes/macrophages, the normal
cellular targets for HIV. However, overexpression of a gene
outside of its physiologic environment can lead to false
positives, where the factor may not actually be involved in
the course of natural infection. Additional support through RNA
interference, mutant studies, and pharmacologic intervention is
thus valuable for the determination of true potential targets.
Mixed lineage kinase 3 (MLK3) was one of the strongest
enhancers of HIV infection identified in the cDNA screen.
Through activation of downstream effectors such as JNK, p38,
and ERK, MLK3 mediates the response of cells to various
stimuli including cytokines and mitogens as well as other stress
signals (Gallo and Johnson, 2002). Activation of MLK3 occurs
as a result of Rac/Cdc42 interactions, which lead to proper
stimulatory phosphorylation and membrane targeting. The
outcome of MLK3 signaling varies depending on the cell type
and stimulus. In neuronal cells, stimulation of MLK3 has been
shown to induce apoptosis through JNK activation, which has
led to the design of inhibitors for the treatment of neurodegen-
erative disorders (Xu et al., 2001). In non-neuronal cells,
overexpression of MLK3 has been shown to promote cell
proliferation and transformation via the Map kinase cascade as
well as mediating morphological changes through microtubule
dynamics (Cha et al., 2006). In the context of T cells, TCR
signaling along with CD28 co-stimulation activates Vav-1,
whose subsequent stimulation of Rac leads to MLK3 activation
of JNK (Hehner et al., 2000a). Along with the CD28-mediated
induction of NFκB through MLK3, this cascade leads to
induction of IL-2 transcription via AP-1 and NFκB binding sites
in the IL-2 promoter and subsequent proliferation (Hehner et al.,
2000b). Early studies on the HIV promoter in the LTR region
showed the presence of binding sites for a variety of
transcription factors also involved in T cell activation, including
AP-1, NFκB, and NF-AT (Cullen, 1991a). While activation of
NFκB has been proven to enhance basal transcription from theHIV-LTR, there are conflicting reports on the ability of AP-1 or
its components (fos and jun) to enhance Tat-independent
transcription. Studies in colon cell lines showed that over-
expression of fos, but not jun, was able to increase basal LTR
activity only in those cells that were susceptible to virus
infection (Roebuck et al., 1993). However, later studies in HeLa
cells indicated that the ability of fos and jun to enhance Tat-
independent transcription was dependent upon the presence of
activated NFκB (Yang et al., 1999). The ability of MLK3 to
stimulate only Tat-dependent transcription within the HeLa cell
background used here is consistent with the AP-1 data in HeLa
cells. It is also possible that MLK3-mediated enhancement of
transcription is through other Tat-dependent transcription
partners, such as pTEFb, although a link between MLK3
signaling and pTEFb function has not been identified (Zhou et
al., 1998). We recently described our data supporting the
involvement of another kinase activated by Rac/Cdc42, Pak1,
on HIV infection (Nguyen et al., 2006). Pak1 has many of the
same downstream effectors as MLK3, including JNK, ERK,
and p38 (Bokoch, 2003); however, Pak1 depletion with siRNA
was shown to inhibit early events in the viral life cycle while
MLK3 depletion did not (data not shown). Despite being
involved in similar signaling cascades, these two kinases exhibit
effects on different stages in the HIV life cycle, demonstrating
the capacity of HIV for utilizing cellular co-factors in multiple
capacities.
Interestingly, one of the other top enhancers was the
interferon-alpha induced protein IFIT1, which has been
shown to be upregulated in a variety of viral infections such
as hepatitis C (HCV) (Wang et al., 2003) as well as in HIV
infection of astrocytes (Kim et al., 2004). While the biological
function of IFIT1 is unknown, it has been reported to be able to
interact with Rho/Rac guanine nucleotide exchange factor, and
thus may help in the activation of Rho/Rac proteins (Ye et al.,
2003). HIV transcription in T cells is induced by Rac activation
downstream of CD28 co-stimulation (Cook et al., 2003), and
recent studies have suggested that statins are able to inhibit HIV
infection by blocking Rho activation (del Real et al., 2004). The
idea that HIV may use an interferon-induced protein to help
facilitate its replication is intriguing and worthy of further study,
especially considering the conflicting reports on the efficacy of
interferon alpha as an anti-HIV agent. Less is known about the
other cDNA hits whose siRNA effects confirmed their
involvement in HIV infection. DNAJC14 is a member of the
J-domain chaperone family involved in protein folding (Chen et
al., 2003), and has been shown to associate with dopamine
receptor in the ER, potentially preventing its cell surface
localization (Bermak et al., 2001). In this capacity, DNAJC14
overexpression could lead to the downregulation of surface
receptors whose natural function inhibits HIV infection or
replication. PITPN is a member of a family of small proteins
involved in the transport of phosphatidylinositol and phospha-
tidylcholine between cell compartments (Morgan et al., 2004).
Because of the involvement of phosphatidylinositol in a variety
of cell signaling cascades, PITPN is poised to regulate those
signaling pathways involving PLC activity: phosphorylation of
PITPN by PKC has been shown to prevent its PI exchange
22 D.G. Nguyen et al. / Virology 362 (2007) 16–25capabilities and attenuate PLC activity (Morgan et al., 2004).
Thus, overexpression of this factor could enhance some
signaling pathways beneficial to the HIV life cycle. Considering
the lack of data in the literature on the biological role of several
of the top cDNA enhancers found in our screen, further
investigation on how these genes impact HIV infection could
also allow the elucidation of their cellular function.
Materials and methods
Cells lines and maintenance
HeLaCD4βgal cells from Dr. Michael Emerman were
obtained through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH (Kimpton and
Emerman, 1992), and were maintained in DMEM supplemen-
ted with 10% FBS, 1× penicillin/streptomycin/L-glutamine,
0.2 mg/ml G418 and 0.1 mg/ml Hygromycin B. Jurkat cells
were maintained in RPMI-1640 supplemented with 10% FBS
and 1× penicillin/streptomycin/L-glutamine. All cell culture
reagents were obtained from Invitrogen.
cDNA screening in HeLaCD4βgal cells
High-throughput cDNA retro-transfection of HeLaCD4βgal
cells was carried out essentially as described (Chanda et al.,
2003). Briefly, individual cDNA of a sub-genomic library en-
compassing 15,000 genes (collection details at http://function.
gnf.org), negative control Sport6GFP cDNA and positive
control Sport6-Tat plasmid were spotted at 40 ng/well in 55
white opaque 384-well plates (Greiner). A solution of 1% Gene
Juice (Novagen) containing 1 μg/ml of an HIV-LTR-Luciferase
reporter plasmid (derived by PCR amplification of the LTR
sequence of strain HxB2) in serum-free Opti-MEM media
(Invitrogen) was added to each well (10 μl) using a Multidrop
apparatus (Titertek) and complexes were allowed to form for
10 min. HeLaCD4βgal cells (1000 cells/30 μl/well in DMEM/
10% FBS) were then added and the plates were incubated
overnight, followed by the addition of 20 μl of DMEM/10%
FBS with 200 ng/ml p24 of HIV-IIIb (Advanced Biotechnol-
ogies Inc.). After 72 h, infection was assessed by measuring
luciferase production using Brite Glo (Promega) and reading on
the CLIPR apparatus (Molecular Devices). The entire library
was run in duplicate. Hits were reconfirmed after growing up
additional cDNA by testing in the original assay and were
sequenced to confirm their identity (Eton Bioscience).
cDNA screen data analysis
For data analysis, the raw signal values are first normalized
by dividing the raw value of a well by the median of all raw
values on the plate where it comes from. When computing the
median, wells designated as control wells are excluded. The
normalized value then represents a fold change above or below
the median of the plate. Prior to averaging or performing other
computations such ratios are log transformed to yield symmetric
ranges between fold changes above and below the median.The remaining computations aim to provide a measure for
each transcript's fold-change value to which degree it is an
outlier, i.e., different from the average fold-change, in a way that
is robust against the high amount of noise present in typical
screening results. The average fold activation or ‘afa’ of the
normalized values x1, x2, …, xn of the n replicates of a particular
well is defined on the basis of a geometric mean of the replicate
values:
afa ¼
expðlÞ if lz0
1
expðlÞ
if l<0 ; with l ¼
Pn
i¼1
logðxiÞ
n
:
8><
>:
In this manner fold activation (μ>0) and fold repression
(μ<0) are represented on the intervals [1, ∞) and (−∞, −1]
respectively. Hence, the dynamic range of activator and
repressor screens can be compared on an equivalent scale.
Next afa is penalized by the standard deviation between
replicates. Specifically, the penalized average fold activation
(pafa or afa/mfa) for the normalized values x1, x2, …, xn of the n
replicates of a particular well is defined as
pafa ¼ afa
mfa
; with mfa ¼ exp
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXn
i¼1
ðlogðxiÞ  lÞ2
n 1
vuuut
0
BBBB@
1
CCCCA:
Note that when the standard deviation is zero, mfa equals 1
and thus in this case afa/mfa=afa. Wells in the generated hitlist
are ranked by their afa/mfa score.Statistical analysis of gene family enrichment
Screening hits were analyzed for identification of statistically
over-represented functional categories. Among our cDNA
screening collection of N genes with any piece of functional
annotations, a subset of n genes were hit picked. If a certain
functional category of size M matches m hits and M–m non-
hits, the probability that m or more genes in the category of
interest occurs in our hitlist by chance in a random hit selection
can be represented by the accumulative hypergeometric
distribution (Zar, 1999):
P N ;n;M ;mð Þ ¼
Xminðn;MÞ
i¼m
M
i
 
N M
n i
 
N
n
  :
Functional categories with smaller P-value therefore are
more likely to reflect true underlying molecular processes. In
this study, the entire gene ontology tree obtained from the GO
database (http://www.geneontology.org), as well as the InterPro
protein family database (http://www.ebi.ac.uk/interpro) was
recursively evaluated. A P-value cutoff of 10−2 was used to
define relevant gene families.
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MLK3 and a kinase-inactive mutant of MLK3 (K144R) in
pcDNA3.1 vector were generously provided by Dr. Zhiheng Xu
(Xu et al., 2001) (Columbia University) and were tested
alongside the MLK3 Origene collection hit in 12-well plates
using a scaled up version of the screen assay. Briefly, 1.28 μg
cDNA/0.32 μg LTR-Luc/32 μl was spotted per well followed by
320 μl of 1% gene juice/Opti-MEM and then 6×104
HeLaCD4βgal cells in 1 ml of DMEM/10% FBS. After 24 h,
cultures were infected with 90 ng p24 of HIV-IIIb, incubated for
3 additional days, and assessed for infection levels using Brite
Glo (Promega) and reading on the CLIPR apparatus (Molecular
Devices).
siRNA
GL2 luciferase siRNA (catalog #D-001100-01-20), and
PITPNá (accession # NM_006224), TRIM28 (accession #
NM_005762), IFIT1 (accession # NM_001548), LYZ (acces-
sion # NM_000239), CORO1A (accession # NM_007074), and
DnaJC14 (accession # NM_032364) SmartPool siRNAs were
obtained from Dharmacon. In the case of GL2 siRNA,
additional amounts of the same sequence were also obtained
from Qiagen. Two siRNA against Tat were synthesized and
pooled for use as a positive control for inhibition of HIV
infection: (1) CUGCUUGUACCAAUUGCUA-d(TT) which
has been previously published (Coburn and Cullen, 2002) and
(2) GCCUUAGGCAUCUCCUAUG-d(TT) which was
designed using the Dharmacon siDESIGN center. MLK3-1
and MLK3-2 siRNA were designed using an algorithm
previously described (Aza-Blanc et al., 2003) and had the
following sequences: (MLK3-1) CCCTGAAGATCACC-
GACTT-d(TT), (MLK3-2) GCTGTTAACAAGCTCACAC-d
(TT). MLK3-3 siRNA was obtained from Dharmacon (catalog
#D-003577-03).
siRNA in HeLaCD4βgal cells
siRNA retro-transfection of HeLaCD4βgal cells was carried
out essentially as described (Aza-Blanc et al., 2003). Briefly,
individual siRNAs were spotted at 14 ng/well in white opaque
or white clear-bottom 384-well plates (Greiner) containing one
siRNA sequence per well. A solution of 2% oligofectamine
(Invitrogen) in serum-free Opti-MEM media (Invitrogen) was
added to each well (10 μl) and complexes were allowed to form
for 15–20 min. All 384-well dispenses were done using a
Multidrop apparatus (Titertek). HeLaCD4βgal cells (1000 cells/
30 μl/well in serum-free Opti-MEM) were then added and the
plates were incubated overnight, followed by the addition of
20 μl of 30% FBS/DMEM with 200 ng/ml of HIV-IIIb
(Advanced Biotechnologies Inc.). After 72 h, infection was
assessed by measuring beta-galactosidase production using an
equal volume of Gal Screen (Applied Biosystems). All 384-well
plate reading was done using the CLIPR apparatus (Molecular
Devices). Twelve replicates were run per 384-well plate and the
data were expressed as percent inhibition compared to thenegative control GL2 siRNA. Cytotoxicity of the siRNA was
measured at 96 h post-transfection by adding equal volume of a
1:4 dilution of Cell Titer Glo (Promega) and reading
luminescence on the CLIPR apparatus, with the data again
expressed as a percent inhibition of viability signal compared to
negative control GL2 siRNA.
siRNA validation by quantitative RT-PCR
siRNA (800 ng) was spotted in 250 μl of serum-free Opti-
MEM (Invitrogen) in 6-well plates followed by the addition of
250 μl of 1.5% Lipofectamine 2000 (Invitrogen) in serum-free
Opti-MEM. Plates were incubated at room temperature for
20 min to allow for complex formation. HeLaCD4βgal cells
(3×105 in 1.5 ml of serum-free Opti-MEM) were then added
and incubated overnight followed by the addition of 1 ml of
30% FBS/DMEM. Cells were harvested 24 h post-transfection
and RNA isolated using the RNeasy kit from Qiagen.
Following normalization, RNA was used as template in one-
step quantitative RT-PCR using reagents from Invitrogen and
performed on the ABI Prism 7900 instrument (Applied
Biosystems Inc.) using the following primer and probe sets
designed with Primer Express software; (1) DNAJC14 forward:
CTTTTCTTTCCATTCCATCTGCTT, DNAJC14 reverse:
TCCCTCAGAGTAAGGCCCTTCT, DNAJC14 probe:
6FAM-CAACTGCCAGGGAACACCTGGAATTC-TAMSp;
(2) IFIT1 forward: GCCTCCTTGGGTTCGTCTATAA, IFIT
reverse: TCAAAGTCAGCAGCCAGTCTCA, IFIT1 probe:
6FAM-AGCCCTGGAGTACTATGAGCGGGCC-TAMSp; (3)
PITPN forward: CGTGGAGGTCCTGGTGAATG, PITPN
reverse: TGCAGGTGGTAGATCTTATGTGTGT, PITPN
probe: 6FAM-CCCTACGAGAAGGACGGTGAGAAAGGC-
TAMSp.
siRNA validation by Western blot
siRNA (800 ng) was spotted in 250 μl of serum-free Opti-
MEM (Invitrogen) in 6-well plates followed by the addition of
250 μl of 1.5% Lipofectamine 2000 (Invitrogen) in serum-free
Opti-MEM. Plates were incubated at room temperature for
20 min to allow for complex formation. HeLaCD4βgal cells
(3×105 in 1.5 ml of serum-free Opti-MEM) were then added
and incubated overnight followed by the addition of 1 ml of
30% FBS/DMEM. Cells were harvested 72 h post-transfection
by scraping and lysed in cell lysis buffer (20 mM HEPES pH
7.2/10 mM KCl/1 mM EDTA/1% Triton X-100/1× protease
inhibitors; Sigma Chemical Co.) for 1 h on ice. Total protein
concentration of the lysates was measured using the Micro-
BCA kit (Promega) and equal protein amounts were loaded onto
4–12% NuPage Bis–Tris gel (Invitrogen) and subjected to
electrophoresis as suggested by the manufacturer. Following
transfer to nitrocellulose, blots were blocked with 5% nonfat
milk in PBST (phosphate-buffered saline with 0.05% Tween-
20) and then subjected to immunoblotting with the following
antibodies; rabbit polyclonal anti-MLK3 and goat–anti-tubulin
antibody from Santa Cruz Biotechnology, HRP-conjugated
goat-anti-rabbit secondary antibody from Sigma Chemical Co.,
24 D.G. Nguyen et al. / Virology 362 (2007) 16–25HRP-conjugated donkey–anti-goat secondary antibody from
Promega. All antibodies were used at dilutions suggested by the
manufacturer and were diluted in 5% nonfat milk in PBST.
Bands were visualized using ECL-plus detection reagent
(Amersham).
siRNA transfection of Jurkat T cells
Jurkat T cells were washed once in PBS, resuspended in
serum-free Opti-MEM (Invitrogen) at high density (2.4×108/
ml) and 50 μl was added to 1 nmol of siRNA (50 μl of 20 μM)
in an 0.2 cm gap cuvette. The mixture was subjected to
electroporation using the BioRad Gene Pulser Xcell module
using conditions suggested by the manufacturer (140 V,
1000 μF, exponential decay) and then transferred to 12 ml of
RPMI supplemented with 10% FBS without antibiotics for 24 h.
Cells were then pelleted, viable cells counted by trypan blue
exclusion, and resuspended at a density of 1.7×106/ml in RPMI
supplemented with 10% FBS and 1XPen/Strep/glutamine. For
infection studies, 300 μl of siRNA-treated cells was added to
wells of a 48-well plate and either 2 ng or 0.5 ng of HIV-IIIb,
corresponding to MOIs of 0.0005 and 0.000125 respectively
based on viral titer provided by the manufacturer, was added to
each well. After 3 additional days, the cells were harvested,
washed 3× in PBS, lysed, and infection was measured by p24
ELISA of the cell lysates. For cytotoxicity, 300 μl of siRNA-
treated cells was added to wells of a 48-well plate and after
3 days, cell viability was measured using Cell Titer Glo
(Promega) and reading on the CLIPR (Molecular Devices) or
using Alamar Blue (TREK systems) and reading on the Acquest
(LJL Biosystems). To determine siRNA efficacy, cell lysates
were prepared and analyzed as in HeLaCD4βgal siRNA
validation studies at 72 h post-electroporation.
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